[PDF][PDF] Adipose‐specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and …
KB Sotiropoulos, A Clermont, Y Yasuda… - The FASEB …, 2006 - Citeseer
KB Sotiropoulos, A Clermont, Y Yasuda, C Rask-Madsen, M Mastumoto, J Takahashi…
The FASEB Journal, 2006•CiteseerIn this study, we investigated the underlying mechanisms that cause the serious adverse
effects of PPAR agonists (rosiglitazone, RSG)—edema and wt gain—in models of diabetes
and insulin resistance with the following aims: 1. To explore the potential involvement of
protein kinase C (PKC) and vascular endothelial growth factor (VEGF), two well-established
vascular permeability factors, on TZD-induced edema; 2. To examine the role of insulin's
effects on the endothelial cells on the regulation of capillary permeability.
effects of PPAR agonists (rosiglitazone, RSG)—edema and wt gain—in models of diabetes
and insulin resistance with the following aims: 1. To explore the potential involvement of
protein kinase C (PKC) and vascular endothelial growth factor (VEGF), two well-established
vascular permeability factors, on TZD-induced edema; 2. To examine the role of insulin's
effects on the endothelial cells on the regulation of capillary permeability.
In this study, we investigated the underlying mechanisms that cause the serious adverse effects of PPAR agonists (rosiglitazone, RSG)—edema and wt gain—in models of diabetes and insulin resistance with the following aims: 1. To explore the potential involvement of protein kinase C (PKC) and vascular endothelial growth factor (VEGF), two well-established vascular permeability factors, on TZD-induced edema; 2. To examine the role of insulin’s effects on the endothelial cells on the regulation of capillary permeability.
Citeseer